Nasdaq:ARCT
Arcturus Therapeutics Holdings Inc.
A clinical-stage biopharma firm leveraging CRISPR technology to develop curative therapies for genetic diseases while maintaining a substantial cash reserve.
Key Metrics
Investment Thesis
Bull Case
Investors may buy this stock due to its transformative potential in the gene editing space, which could yield high-value curative therapies if clinical trials succeed. The company holds a robust cash balance of $230.9M that provides ample runway to fund ongoing research and development activities without immediate distress. Strategic partnerships and a first-mover advantage in specific genetic disease indications offer significant upside potential upon regulatory approval.
Bear Case
The stock carries high risk as the company is still in clinical stages with no commercialized products generating sustainable recurring revenue. Negative net income trends over the last five years and increasing losses suggest that the path to profitability is distant and dependent on successful, costly trials. Investors should be wary of the rapid revenue contraction and the potential need for future dilution to cover the substantial operating expenses.
About Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for genetic diseases using CRISPR-based gene editing technologies. The company serves patients with severe monogenic disorders through its proprietary platform, aiming to address unmet medical needs in the rare disease sector. Key products are currently in various stages of clinical development, with revenue primarily driven by research services and collaborations.
Analysis
Management Discussion
Despite generating $82.0M in revenue, the company reported a net loss of $65.8M and negative operating cash flow of $74.3M for 2025, reflecting its capital-intensive clinical development phase. The business saw a sharp decline in revenue from previous years, dropping from $152.3M in 2024 to $82.0M, likely due to the transition period between collaboration payments and new trial milestones. Management has managed to maintain a healthy current ratio, but the retained earnings deficit of over half a billion dollars highlights the long-term capital needs inherent in this stage of biotechnology.
Industry Overview
The biotechnology industry, particularly gene editing, is characterized by high failure rates but offers the potential for paradigm-shifting treatments for rare genetic diseases. Competition is intensifying as major pharmaceutical companies enter the field, though specialized players like Arcturus retain niche advantages in specific disease areas. The sector currently relies heavily on external funding and strategic partnerships to bridge the gap between scientific discovery and commercialization.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $206.0M | $166.8M | $152.3M | $82.0M |
| Cost of Revenue | $0 | $0 | $0 | $0 |
| Gross Profit | $206.0M | $166.8M | $152.3M | $82.0M |
| Operating Expenses | $193.8M | $245.0M | $248.0M | $158.3M |
| Operating Income | $12.2M | $-78.2M | $-95.7M | $-76.3M |
| R&D | $147.8M | $192.1M | $195.2M | $112.2M |
| G&A | $46.1M | $52.9M | $52.8M | $46.1M |
| Stock-Based Comp | $30.6M | $34.6M | $38.0M | $25.4M |
| D&A | $1.5M | $3.0M | $3.5M | $3.0M |
| Other OpEx | $0 | $0 | $0 | $0 |
| Non-Operating Income | $-1.5M | $50.3M | $14.7M | $10.5M |
| Pre-Tax Income | $10.6M | $-27.9M | $-80.9M | $-65.8M |
| Income Tax | $1.3M | $1.8M | $-4.0K | $0 |
| Continuing Ops | $9.3M | $-29.7M | $-80.9M | $-65.8M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $9.3M | $-29.7M | $-80.9M | $-65.8M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $9.3M | $-29.7M | $-80.9M | $-65.8M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $403.3M | $386.6M | $306.0M | $241.4M |
| Cash & Equivalents | $391.9M | $292.0M | $237.0M | $230.9M |
| Accounts Receivable | $2.8M | $32.1M | $4.0M | $5.6M |
| Other Current Assets | $8.7M | $62.5M | $65.0M | $5.0M |
| Long-Term Assets | $47.1M | $42.8M | $38.1M | $29.7M |
| PP&E (Net) | $12.4M | $12.4M | $9.5M | $6.7M |
| Operating Leases | $32.5M | $28.5M | $26.7M | $21.1M |
| Other LT Assets | $2.1M | $1.9M | $1.9M | $1.9M |
| Total Assets | $450.4M | $429.4M | $344.1M | $271.1M |
| Current Liabilities | $127.0M | $82.0M | $65.5M | $36.4M |
| Accounts Payable | $7.4M | $5.3M | $7.2M | $4.2M |
| Current Debt | $60.7M | — | — | — |
| Current Leases | $3.9M | $4.3M | $3.6M | $4.2M |
| Other Current Liab | $24.8M | $40.5M | $16.0M | $4.0M |
| Long-Term Liabilities | $53.1M | $68.9M | $37.6M | $20.8M |
| LT Operating Leases | $30.2M | $25.9M | $25.0M | $20.8M |
| Other LT Liab | $22.9M | $43.0M | $12.6M | $0 |
| Total Liabilities | $180.1M | $150.9M | $103.1M | $57.2M |
| Shareholders' Equity | $270.3M | $278.5M | $241.0M | $214.0M |
| Paid-In Capital | $608.4M | $646.4M | $689.8M | $728.5M |
| Retained Earnings | $-338.1M | $-367.9M | $-448.8M | $-514.6M |
| Total L&E | $450.4M | $429.4M | $344.1M | $271.1M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $9.3M | $-29.7M | $-80.9M | $-65.8M |
| Non-Cash Adjustments | $32.5M | $-48.0M | $97.8M | $41.2M |
| Working Capital Changes | $-9.9M | $59.6M | $-76.6M | $-49.7M |
| Cash from Operations | $32.0M | $-18.1M | $-59.7M | $-74.3M |
| Capital Expenditures | $7.7M | $2.9M | $648.0K | $230.0K |
| Cash from Investing | $-7.7M | $-2.9M | $-648.0K | $-230.0K |
| Cash from Financing | $-2.9M | $-24.1M | $5.4M | $13.4M |
| FX Effect | $0 | $0 | $0 | $0 |
| Net Change in Cash | $21.4M | $-45.1M | $-55.0M | $-61.1M |
| Beginning Cash | $372.6M | $394.0M | $348.9M | $293.9M |
| Ending Cash | $394.0M | $348.9M | $293.9M | $232.8M |
Frequently Asked Questions
How does Arcturus Therapeutics Holdings Inc. make money?
The company's financials indicate a heavy reliance on high-cost Research and Development (R&D) expenditures, which significantly outpaced revenue in 2025. Revenue streams appear dominated by contract research services or early-stage collaboration fees rather than commercialized drug sales, given the absence of cost of revenue and gross profit equal to total revenue. The financial structure suggests a focus on pipeline advancement rather than current product commercialization.
What are the main risks for ARCT?
The company faces significant financial risk due to negative operating cash flow and a narrowing cash balance, requiring future equity issuance or capital raises to sustain operations. There is substantial clinical development risk as the value of the business depends entirely on successful trial outcomes for its genetic disease candidates. Regulatory hurdles in the rare disease space and potential patent challenges could delay product launches or impact market exclusivity.
What is ARCT's competitive advantage?
The company possesses exclusive access to advanced CRISPR gene editing technology, offering potential for curative treatments in rare disease markets with limited competition. Its substantial cash position relative to annual burn rate provides a long runway to advance multiple clinical programs without immediate dilution pressure. A strong intellectual property portfolio surrounding its proprietary editing tools creates a high barrier to entry for competitors.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.